Pfizer Escapes FCA Suit Over Anti-Fungal Drug Promotions
By Kurt Orzeck (November 25, 2013, 8:38 PM EST) -- A Massachusetts federal judge on Friday dismissed an ex-Pfizer Inc. manager's False Claims Act qui tam suit accusing the drug giant of a long-running and illegal campaign to promote off-label use of anti-fungal drugs, finding the claims were too vague.
U.S. District Judge Nathaniel M. Gorton decided the claims were insufficient because they didn't contain enough details accusing Pfizer of submitting a false claim to the federal government over Vfend and Eraxis.
Paul Worsfold, a former district manager at Pfizer, said his ex-employer recklessly and unnecessarily endangered patient health by encouraging unapproved uses of Vfend and Eraxis. Alleged offenses included promoting...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!